The global Duchenne muscular dystrophy treatment market is estimated to be valued at US$ 2 billion in 2024 and is expected to exhibit a CAGR of 47% over the forecast period 2024-2028.
Key Takeaways
Key players operating in the Duchenne muscular dystrophy treatment are Sarepta Therapeutics, Pfizer, PTC Therapeutics, Summit Therapeutics, and others. Sarepta Therapeutics' Exondys 51 was the first FDA-approved treatment specifically for DMD in 2016.
The Duchenne Muscular Dystrophy Treatment Market Trend provides significant growth opportunities due to ongoing clinical trials evaluating gene therapy and other novel treatment approaches. Major pharmaceutical companies are accelerating their efforts to develop first-ever curative therapies.
Advancements in gene therapy hold promise to potentially cure DMD by replacing or repairing the defective dystrophin gene. Several gene therapy candidates are under evaluation in late-stage clinical trials with encouraging initial safety and efficacy results.
Market Drivers
Increasing diagnosis rate primarily due to widespread availability of genetic testing and counselling is a key factor fueling demand for DMD treatments. Growing DMD patient population worldwide along with rising healthcare expenditures provide a strong foundation for market growth over the forecast period. Additionally, robust pipeline of novel drug candidates and a high unmet need for safe and effective therapies are expected to propel the market.
Current challenges in Duchenne Muscular Dystrophy Treatment Market
The Duchenne muscular dystrophy (DMD) treatment market faces several challenges currently. The first major challenge is lack of approved drug therapies. While there are several drug candidates in clinical trials, currently there is no cure for DMD. The only approved treatment is corticosteroids which only help slow the progression but do not cure the disease. Developing effective therapies is challenging due to complexity of disease pathology. Another major challenge is lack of early diagnosis. Symptoms usually appear in early childhood but diagnosis often gets delayed. This delays the start of available treatment approaches. High cost of treatment also poses a challenge as patients may require lifelong therapy. Managing symptoms over the course of the disease also adds to treatment costs. Lack of awareness about early signs of DMD is another challenge area that needs to be addressed.
Get more insights on Duchenne Muscular Dystrophy Treatment Market
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian